Skip to content
TriangleGet started
← Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer

FOR PATIENTS · SOURCE READING

Treatment of Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancers

Source: Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancers Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: November 22, 2024 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.

For information about the treatments listed below, see the Treatment Option Overview section.

Source links and citations

Treatment of recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer may include:

Source links and citations

Chemotherapy using one or more anticancer drugs.

Source links and citations

Targeted therapy with a poly (ADP-ribose) polymerase (PARP) inhibitor (olaparib, rucaparib, or niraparib) with or without chemotherapy.

Source links and citations

Chemotherapy and/or targeted therapy (bevacizumab).

Source links and citations

A clinical trial of hyperthermic intraperitoneal chemotherapy (HIPEC) during surgery.

Source links and citations

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Source links and citations

Preserved source evidence · Independent clinical review pending · Not medical advice